Technical Analysis for VEGPF - Vectura Group Plc

Grade Last Price % Change Price Change
grade D 0.9818 0.68% 0.0066
VEGPF closed up 0.68 percent on Thursday, July 25, 2019, on 27 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical VEGPF trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Gapped Up Strength 0.00%
Narrow Range Bar Range Contraction 0.68%
Down 3 Days in a Row Weakness 0.68%
Down 4 Days in a Row Weakness 0.68%
Gapped Down Weakness 0.68%
Narrow Range Bar Range Contraction -0.08%
BB Squeeze Ended Range Expansion -0.08%

Older signals for VEGPF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD. Its generic partnering products include flutiform, VR315, VR506, VR730, VR632, VR2081, VR410, and Ellipta for the treatment of asthma; and Phase I clinical stage product is the VR475 (US) for the treatment of severe adult asthma. The company's Phase II clinical stage products comprise VR465 for treating respiratory syncytial virus infection; VR647 for the treatment of paediatric asthma; and VR736 for the treatment severe influenza. Its Phase III clinical stage products include QVM149 for the treatment of asthma; and VR475 (EU) for the treatment of severe adult asthma. The company also provides dry powder inhalers; pressurized meter dose inhalers; and smart nebulizers. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Medicine Health Clinical Medicine Pharmaceutical Products European Union Dosage Forms Asthma Chronic Obstructive Pulmonary Disease Respiratory Therapy Chronic Lower Respiratory Diseases Combination Drugs Copd Pulmonary Arterial Hypertension Treatment Of Asthma And Chronic Obstructive Pulmonary Disease Clinical Stage Product Dry Powder Inhaler
Is VEGPF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 2.51
52 Week Low 0.845
Average Volume 71,293
200-Day Moving Average 0.0
50-Day Moving Average 1.013
20-Day Moving Average 0.9985
10-Day Moving Average 0.9954
Average True Range 0.043
ADX 9.43
+DI 45.1989
-DI 50.4244
Chandelier Exit (Long, 3 ATRs ) 0.981
Chandelier Exit (Short, 3 ATRs ) 1.04
Upper Bollinger Band 1.1024
Lower Bollinger Band 0.8946
Percent B (%b) 0.42
BandWidth 20.811217
MACD Line -0.0083
MACD Signal Line -0.0093
MACD Histogram 0.001
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.9818
Resistance 3 (R3) 0.9818 0.9818 0.9818
Resistance 2 (R2) 0.9818 0.9818 0.9818 0.9818
Resistance 1 (R1) 0.9818 0.9818 0.9818 0.9818 0.9818
Pivot Point 0.9818 0.9818 0.9818 0.9818 0.9818
Support 1 (S1) 0.9818 0.9818 0.9818 0.9818 0.9818
Support 2 (S2) 0.9818 0.9818 0.9818 0.9818
Support 3 (S3) 0.9818 0.9818 0.9818
Support 4 (S4) 0.9818